B
BioAge Labs, Inc. (BIOA)
NMS – Real Time Price. Currency in USD
18.19
+0.03 (0.17%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
18.19
+0.03 (0.17%)
At close: May 12, 2026, 4:00 PM EDT
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
| Name | Position |
|---|---|
| Dr. Dov A. Goldstein M.B.A., M.D. | Chief Financial Officer |
| Dr. Eric Morgen M.D. | Co-Founder, COO & Director |
| Dr. Kristen Fortney Ph.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director |
| Dr. Paul D. Rubin M.D. | Chief Medical Officer & Executive VP of Research |
| Dr. Peng Leong M.B.A., Ph.D. | Chief Business Officer & Therapeutic Area Head of Brain Aging |
| Mr. BJ Sullivan Ph.D. | Chief Strategy Officer |
| Mr. Rusty Montgomery Ph.D. | Senior Vice President of Research |
| Mr. Shane Barton CPA | Senior Vice President of Finance & Accounting |
| Ms. Ann C. Neale RN BSN | Chief Development Officer |
| Ms. Julie Gammelgard | Senior Vice President of People |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | 8-K | bioa-20260508.htm |
| 2026-04-21 | DEFA14A | bioa_2026_defa14a.htm |
| 2026-03-24 | S-3ASR | bioa-20260324.htm |
| 2026-01-22 | 8-K | bioa-20260121.htm |
| 2026-01-12 | 8-K | bioa-20260112.htm |
| 2025-12-04 | 8-K | bioa-20251204.htm |
| 2025-11-06 | 10-Q | bioa-20250930.htm |
| 2025-11-05 | S-3/A | resale_s-3a_2025_-_no_xb.htm |
| 2025-10-02 | S-3 | bioa-20251002.htm |
| 2025-08-06 | 8-K | bioa-20250806.htm |